Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Presented at ECE 2024

May 21, 2024

Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Adrenal Product / Technology

←Applauding Our Asian American Members: Endocrine News Celebrates Asian American and Pacific Islander Heritage Month

Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs to Be Presented at ENDO 2024→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today